open access

Vol 50, No 1 (2018)
Published online: 2017-11-11
Submitted: 2017-10-16
Accepted: 2017-11-06
Get Citation

A whiter shade of pale: the ongoing challenge of haemorrhagic shock

David J.J. Muckart, Manu L.N.G. Malbrain
DOI: 10.5603/AIT.a2017.0060
Pubmed: 29150998
Anaesthesiol Intensive Ther 2018;50(1):1-6.

open access

Vol 50, No 1 (2018)
Published online: 2017-11-11
Submitted: 2017-10-16
Accepted: 2017-11-06


Not available


Not available
Get Citation
About this article

A whiter shade of pale: the ongoing challenge of haemorrhagic shock


Anaesthesiology Intensive Therapy


Vol 50, No 1 (2018)



Published online






Bibliographic record

Anaesthesiol Intensive Ther 2018;50(1):1-6.


David J.J. Muckart
Manu L.N.G. Malbrain

References (47)
  1. Pfeifer R, Teuben M, Andruszkow H, et al. Mortality Patterns in Patients with Multiple Trauma: A Systematic Review of Autopsy Studies. PLoS One. 2016; 11(2): e0148844.
  2. Gross SD. Wound and other injuries. In: Gross SD. ed. A manual of military surgery. JB Lippincott and Co, Philadelphia 1861: 45–73.
  3. Millham FH. A brief history of shock. Surgery. 2010; 148(5): 1026–1037.
  4. Blalock A. Acute circulatory failure as exemplified by shock and haemorrhage. Surg Gynecol Obstet. 1934; 58: 551.
  5. Shires T, Coln D, Carrico J, et al. Fluid therapy in hemorrhagic shock. Arch Surg. 1964; 88: 688–693.
  6. Bailey H. Treatment of shock and other methods of resuscitation. In: Bailey H. ed. Emergency Surgery. John Wright and Sons Ltd, Bristol 1953: 43–47.
  7. Barbee RW, Reynolds PS, Ward KR. Assessing shock resuscitation strategies by oxygen debt repayment. Shock. 2010; 33(2): 113–122.
  8. Hubbard WJ, Bland KI, Chaudry IH. The role of the mitochondrion in trauma and shock. Shock. 2004; 22(5): 395–402.
  9. Bryson W. A short history of nearly everything. Broadway Books. 2003.
  10. Paxian M, Bauer I, Rensing H, et al. Recovery of hepatocellular ATP and "pericentral apoptosis" after hemorrhage and resuscitation. FASEB J. 2003; 17(9): 993–1002.
  11. Hsu YM, Haas T, Cushing M. Massive transfusion protocols: current best practice. Int J Clin Trans Med. 2016; 4: 15–27.
  12. Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016; 20: 100.
  13. Holcomb JB, del Junco DJ, Fox EE, et al. PROMMTT Study Group. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013; 148(2): 127–136.
  14. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313: 471–82.
  15. Kozar RA, Peng Z, Zhang R, et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg. 2011; 112(6): 1289–1295.
  16. Torres L, Sondeen J, Salgado C, et al. Comparison of plasma and 5% albumin resuscitation in preserving endothelial glycocalyx and microvascular permeability in vivo after severe haemorrhagic shock in rats. FASEB J. 2014; 28 (Suppl).
  17. Inaba K, Branco BC, Rhee P, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg. 2010; 210(6): 957–965.
  18. Fowler A, Perry DJ. Laboratory monitoring of haemostasis. Anaesthesia. 2015; 70 Suppl 1: 68–72, e24.
  19. Keene DD, Nordmann GR, Woolley T. Rotational thromboelastometry-guided trauma resuscitation. Curr Opin Crit Care. 2013; 19(6): 605–612.
  20. Abdelfattah K, Cripps MW. Thromboelastography and Rotational Thromboelastometry use in trauma. Int J Surg. 2016; 33(Pt B): 196–201.
  21. Heim C, Steurer M, Brohi K. Damage control resuscitation: more than just transfusion strategies. Curr Anesthesiol Rep. 2016; 6(1): 72–78.
  22. Wise R, Faurie M, Malbrain ML, et al. Strategies for Intravenous Fluid Resuscitation in Trauma Patients. World J Surg. 2017; 41(5): 1170–1183.
  23. Frith D, Brohi K, Frith D, et al. Animal models of trauma-induced coagulopathy. Thromb Res. 2012; 129(5): 551–556.
  24. Hébert PC, Wells G, Blajchman MA, et al. A Multicenter, randomized, controlled trial of transfusion requirements in critical care. N Engl J Med. 1999; 340: 409–417.
  25. Lamb CM, MacGoey P, Navarro AP, et al. Damage control surgery in the era of damage control resuscitation. Br J Anaesth. 2014; 113(2): 242–249.
  26. Shakur H, Roberts I, Bautista R, et al. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734): 23–32.
  27. Wafaisade A, Lefering R, Bouillon B, et al. TraumaRegister DGU. Prehospital administration of tranexamic acid in trauma patients. Crit Care. 2016; 20(1): 143.
  28. Roberts I, Shakur H, Afolabi A, et al. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771): 1096–101, 1101.e1.
  29. Valle EJ, Allen CJ, Van Haren RM, et al. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014; 76(6): 1373–1378.
  30. Davidson RA, Guo T, Bridges DR, et al. Does it work or not? Clinical versus statistical significance. Chest. 19794; 106: 932–934.
  31. Gruen RL, Jacobs IG, Reade MC. Trauma and tranexamic acid. Med J Aust. 2013; 199(5): 310–311.
  32. Régnier MA, Raux M, Le Manach Y, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012; 117(6): 1276–1288.
  33. Ince C, Mik EG. Microcirculatory and mitochondrial hypoxia in sepsis, shock, and resuscitation. J Appl Physiol (1985). 2016; 120(2): 226–235.
  34. Cheddie S, Muckart DJJ, Hardcastle TC. Base deficit as an early marker of coagulopathy in trauma. S Afr J Surg. 2013; 51(3): 88–90.
  35. Grey B, Rodseth RN, Muckart DJJ. Early fracture stabilisation in the presence of subclinical hypoperfusion. Injury. 2013; 44(2): 217–220.
  36. Wiedemann HP, Wheeler AP, Bernard GR, et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006; 354(24): 2564–2575.
  37. Malbrain ML, Marik PE, Witters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014; 46(5): 361–380.
  38. Dare AJ, Phillips ARJ, Hickey AJR, et al. A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome. Free Radic Biol Med. 2009; 47(11): 1517–1525.
  39. Corrêa TD, Jakob SM, Takala J. Mitochondrial function in sepsis. Crit Care Horizons. 2015; 1: 31–41.
  40. Muckart DJJ, Bhagwanjee S. The ACCP/SCCM Consensus Conference definitions of the Systemic Inflammatory response syndrome (SIRS) and allied disorders in critically injured patients. Crit Care Med. 1997; 25: 1789–1795.
  41. Hwang PF, Porterfield N, Pannell D, et al. Trauma is danger. J Transl Med. 2011; 9: 92.
  42. Zhang Q, Raoof M, Chen Yu, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010; 464(7285): 104–107.
  43. Krysko DV, Agostinis P, Krysko O, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011; 32(4): 157–164.
  44. Simmons JD, Lee YL, Mulekar S, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg. 2013; 258(4): 591–596.
  45. Chaudry IH. Use of ATP following shock and ischemia. Ann N Y Acad Sci. 1990; 603: 130–40; discussion 140.
  46. Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010; 10(9): 3223–3230.
  47. Mirjalili F, Soltani M, Chen P. Nanotechnology in Drug Delivery Systems. 2012; 4: 275–288.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: